# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN-TD
- Date: 1980-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Evangeline Moss, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

Establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapy. **S**

## Historical basis

- Barbara Jordan was born on February 21, 1936, in Houston, Texas, the youngest of three daughters, and grew up in Houston's Fifth Ward. She graduated magna cum laude from Texas Southern University in 1956 and earned a law degree from Boston University in 1959. **D**
- In 1966 she was elected to the Texas Senate, the first Black state senator since 1883. In 1972 she was elected to the U.S. House of Representatives from Houston, the first Black woman from a Southern state to serve in Congress. As a member of the House Judiciary Committee during the 1974 impeachment hearings she said, "My faith in the Constitution is whole, it is complete, it is total." **D**
- In 1976 she gave the keynote address at the Democratic National Convention, the first woman and the first African American to do so. **D**
- She did not seek a fourth term and left the House in 1979, downplaying reports about her poor health and citing her "internal compass." She became the Lyndon Baines Johnson Public Service Professor at the LBJ School of Public Affairs of the University of Texas at Austin, where she taught until the early 1990s. **D**
- In her later years in the House she walked with a cane, which she attributed at the time to "a bum knee"; a disability-press account written after her death says this was the first adaptive equipment her multiple sclerosis required, and that she did not openly acknowledge the disease for years. **D**
- It was later revealed that she had been diagnosed with multiple sclerosis around the time she left Congress. The year of the diagnosis is not stated in the obituaries and reference works consulted. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- She wants to keep teaching and speaking without her health becoming the subject. **S**
- She wants to know whether any treatment can slow the disease. **S**
- She wants to stay safe on her feet and to have energy left at the end of a teaching day. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- Cholecalciferol (vitamin D3) 1954 units (50 mcg) oral capsule, one capsule daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1978: Walking difficulty needing a cane in her last years in the House, attributed publicly at the time to a knee problem **D** (CLM-0005)
- 1979: Multiple sclerosis diagnosed around the time she left Congress, as later revealed; records of that evaluation are not available to this clinic **D** (CLM-0006)

## Procedures and immunizations

- 1980-03-02 to 1980-03-02: Bladder scan for post-void residual volume **S**


## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

White cells: 6.4 10*3/uL; Lymphocytes (absolute): 1.9 10*3/uL; Hemoglobin: 13.2 g/dL; Platelets: 262 10*3/uL; Creatinine: 0.78 mg/dL; eGFR (CKD-EPI 1975): 96 mL/min/1.73 m²; ALT: 18 U/L; AST: 20 U/L; Alkaline phosphatase: 72 U/L; Total bilirubin: 0.5 mg/dL; TSH: 1.8 mIU/L; Vitamin B12: 520 pg/mL; 25-hydroxyvitamin D: 17 ng/mL (low); IgG: 1080 mg/dL; IgM: 110 mg/dL; IgA: 210 mg/dL; JC virus antibody index: 0.14; PHQ-9: 6. All results are synthetic.

BP 124/78 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 84 kg; BMI 28.1 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, precise and articulate; mood steady; frustrated by fatigue; PHQ-9 score 6, mostly from fatigue and sleep items; no thoughts of self-harm. Functional status: Walks about 100 meters with a cane in her right hand before needing to rest (EDSS 6.0); timed 25-foot walk 11.2 seconds; climbs stairs with a rail; independent in self-care; drives; tires by mid-afternoon. Physical examination is intentionally limited. **S**

## Assessment

1. Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine; status draft. **S**
2. Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls; status draft. **S**
3. Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual; status draft. **S**
4. Vitamin D deficiency; status draft. **S**

## Plan

- Confirm and classify the diagnosis: MRI of the brain and the cervical and thoracic spine with gadolinium to the MAGNIMS-CMSC-NAIMS protocol, read against the 1971 McDonald criteria; exclude mimics with vitamin B12, TSH and HIV; request the records of the original evaluation. Guideline: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021) **S**
- Neurology (multiple sclerosis) consultation to confirm and classify the disease and advise on disease-modifying therapy, its monitoring, vaccination, symptom care and MRI follow-up. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021) **S**
- Screening before any disease-modifying therapy: hepatitis B surface antigen, core antibody and surface antibody; quantitative immunoglobulins; liver tests; blood count with lymphocytes; varicella and measles immunity; tuberculosis blood test; HIV and hepatitis C; JC virus antibody; and vaccines brought up to date, inactivated vaccines at least two weeks and live vaccines at least four weeks before the first dose. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); Adult Immunization Schedule by Age (2026) **S**
- Relapse and pseudo-relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection and fever first, because infection and heat can bring back old symptoms; written card for her bag. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Multiple sclerosis in adults: management (NG220) (2022) **S**
- Mobility, spasticity and falls: physical therapy evaluation for gait, strengthening, stretching, balance and a home exercise program; review of walking aids, with forearm crutches or a rollator and a scooter for long distances when she wants them; home safety review; daily stretching. Guideline: Multiple sclerosis in adults: management (NG220) (2022); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
- Bladder: post-void residual today, timed voiding, fluids earlier in the day, less caffeine, pelvic floor exercises, and a medicine if urgency persists; urine check for any burning, fever or sudden worsening. Guideline: Multiple sclerosis in adults: management (NG220) (2022) **S**
- Fatigue and heat sensitivity: energy conservation and pacing with an occupational therapy review, teaching sessions placed in the morning where she chooses, cooling garments, air conditioning, cool drinks, and aerobic exercise such as pool exercise in cool water. Guideline: Multiple sclerosis in adults: management (NG220) (2022) **S**
- Work: a letter to her employer, with her consent, describing her functional needs (an accessible teaching room near an elevator, a chair and lectern for lectures, reserved parking near her building, and flexibility for medical appointments) without naming the diagnosis; she decides what to disclose. Guideline: Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026) **S**
- Bone health: vitamin D3 with a recheck, calcium from food, weight-bearing exercise, fall prevention, and bone density at the preventive visit because of reduced mobility and earlier steroid courses. Guideline: Multiple sclerosis in adults: management (NG220) (2022); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
- Mood and cognition: PHQ-9 at intake and every six months; ask about concentration and word-finding; counseling offered at any time. Guideline: Multiple sclerosis in adults: management (NG220) (2022); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**

## Guideline basis

- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018), American Academy of Neurology (Neurology)
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017), International Panel on Diagnosis of Multiple Sclerosis (Lancet Neurology)
- 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021), MAGNIMS, CMSC and NAIMS (Lancet Neurology)
- Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019), American Academy of Neurology (Neurology)
- Multiple sclerosis in adults: management (NG220) (2022), National Institute for Health and Care Excellence
- Accommodation and Compliance: Multiple Sclerosis (2026), Job Accommodation Network (U.S. Department of Labor)
- Introduction to the Americans with Disabilities Act (2026), U.S. Department of Justice
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026), Aether Forge
